Parkinson disease: systemic and orofacial manifestations, medical and dental management.
暂无分享,去创建一个
R. Ettinger | A. Friedlander | M. Mahler | K. Norman | Arthur H Friedlander | Michael Mahler | Keith M Norman | Ronald L Ettinger
[1] E. D. Hodges,et al. Management of orofacial manifestations of Parkinson's disease with splint therapy: a case report. , 1993, Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry.
[2] M. Asanuma,et al. Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and Parkinson's disease. , 2008, Current pharmaceutical design.
[3] Yunling E. Du,et al. Subthalamic stimulation for Parkinson disease: determination of electrode location necessary for clinical efficacy. , 2005, Neurosurgical focus.
[4] Dagmar Verbaan,et al. Assessment of psychiatric complications in Parkinson's disease: The SCOPA‐PC , 2007, Movement disorders : official journal of the Movement Disorder Society.
[5] E. Yano,et al. Oral health of patients with Parkinson's disease: factors related to their better dental status. , 2003, The Tohoku journal of experimental medicine.
[6] C. Clarke,et al. Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease , 2000, Journal of neurology, neurosurgery, and psychiatry.
[7] J. Matsumoto,et al. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. , 2005, Parkinsonism & related disorders.
[8] R. Palm,et al. Selegiline slows the progression of the symptoms of Parkinson disease , 2006, Neurology.
[9] W. Weiner,et al. Parkinson's disease. Diagnosis and the initiation of therapy. , 2005, Minerva medica.
[10] P. Lamey,et al. Burning mouth in Parkinson's disease sufferers. , 1998, Gerodontology.
[11] L. Findley,et al. Abnormality of taste and smell in Parkinson's disease. , 2009, Parkinsonism & related disorders.
[12] Daniel Tarsy,et al. BEATING A DEAD HORSE: DOPAMINE AND PARKINSON DISEASE , 2008, Neurology.
[13] F. Lobbezoo,et al. Dental implications of some common movement disorders: a concise review. , 2007, Archives of oral biology.
[14] M. Borg,et al. The role of radiation therapy in the management of sialorrhea. , 1998, International journal of radiation oncology, biology, physics.
[15] F. Stocchi. Optimising levodopa therapy for the management of Parkinson’s disease , 2005, Journal of neurology.
[16] K. Kashihara. Weight loss in Parkinson’s disease , 2006, Journal of Neurology.
[17] L. Criddle,et al. A 79-year-old man with an impalement injury of his face. , 2004, Journal of emergency nursing: JEN : official publication of the Emergency Department Nurses Association.
[18] Larry M Baddour,et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Card , 2007, Circulation.
[19] R. Hauser,et al. Advances in the Pharmacologic Management of Early Parkinson Disease , 2007, The neurologist.
[20] H. Reichmann,et al. Olfactory function in idiopathic Parkinson's disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients , 2002, Journal of Neural Transmission.
[21] M. Unosson,et al. Does l‐dopa treatment contribute to reduction in body weight in elderly patients with Parkinson's disease? , 2005, Acta neurologica Scandinavica.
[22] L. B. Aytés,et al. Salivary gland application of botulinum toxin for the treatment of sialorrhea , 2007 .
[23] Paolo Barone,et al. International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study , 2006, Movement disorders : official journal of the Movement Disorder Society.
[24] N. Solomon. Assessment of tongue weakness and fatigue. , 2004, The International journal of orofacial myology : official publication of the International Association of Orofacial Myology.
[25] H. Weber,et al. Clinical outcomes of three Parkinson's disease patients treated with mandibular implant overdentures. , 2000, Clinical oral implants research.
[26] D. Aarsland,et al. Cognitive Predictors of Dementia in Parkinson’s Disease: A Community-Based, 4-Year Longitudinal Study , 2005, Journal of geriatric psychiatry and neurology.
[27] T. Osterberg,et al. Influence of Parkinson's disease on oral health. , 1992, Acta odontologica Scandinavica.
[28] J. Fiske,et al. Parkinson's disease and oral care. , 2000, Dental update.
[29] K. Marder,et al. Pooled analysis of tobacco use and risk of Parkinson disease. , 2007, Archives of neurology.
[30] Neeraj Kumar,et al. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. , 2006, Archives of neurology.
[31] D. Ryglewicz,et al. Taste responses in patients with Parkinson’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[32] T. O'dwyer,et al. The surgical management of drooling--a 15 year follow-up. , 1997, Clinical otolaryngology and allied sciences.
[33] W. Weiner,et al. Practice Parameter: Diagnosis and prognosis of new onset Parkinson disease (an evidence-based review) , 2006, Neurology.
[34] Jeri Logemann,et al. Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT®): a pilot study , 2002, INTERSPEECH.
[35] G Rees Cosgrove,et al. Experience with Microelectrode Guided Subthalamic Nucleus Deep Brain Stimulation , 2006, Neurosurgery.
[36] J. Yagiela,et al. Adverse drug interactions in dental practice: interactions associated with vasoconstrictors. Part V of a series. , 1999, Journal of the American Dental Association.
[37] E. Tolosa,et al. The diagnosis of Parkinson's disease , 2006, The Lancet Neurology.
[38] K. Cook,et al. Effect of social support on informed consent in older adults with Parkinson disease and their caregivers , 2007, Journal of Medical Ethics.
[39] A. Lees,et al. Anticholinergics for symptomatic management of Parkinson's disease. , 2002, The Cochrane database of systematic reviews.
[40] D. Michalek,et al. Weight change and body composition in patients with Parkinson's disease. , 1995, Journal of the American Dietetic Association.
[41] B. Thanvi,et al. Psychosis in Parkinson’s disease , 2005, Postgraduate Medical Journal.
[42] S. Shibuya,et al. Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study. , 2005, Journal of neurosurgery.
[43] Gang Hu,et al. Coffee and tea consumption and the risk of Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.
[44] K. Kessler,et al. Differential effects of various treatment combinations on cardiovascular dysfunction in patients with Parkinson's disease , 2004, Acta neurologica Scandinavica.
[45] E. Winocur,et al. Drugs and bruxism: a critical review. , 2003, Journal of orofacial pain.
[46] John G Nutt,et al. Clinical practice. Diagnosis and initial management of Parkinson's disease. , 2005, The New England journal of medicine.
[47] K. Kessler,et al. Determinants of autonomic dysfunction in idiopathic Parkinson’s disease , 2005, Journal of Neurology.
[48] K. Winge,et al. Prevalence of bladder dysfunction in Parkinsons disease , 2006, Neurourology and urodynamics.
[49] G. Paulson,et al. Relationship of oral microflora with oral health status in Parkinson's disease. , 1994, Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry.
[50] R. Hilker,et al. Dementia in Parkinson disease , 2005, Neurology.
[51] C. Sapienza,et al. Voluntary Cough Production and Swallow Dysfunction in Parkinson’s Disease , 2008, Dysphagia.
[52] John G. Nutt,et al. Diagnosis and Initial Management of Parkinson's Disease , 2005 .
[53] D. Castell,et al. Swallowing and esophageal function in Parkinson's disease. , 1995, The American journal of gastroenterology.
[54] G. Nappi,et al. Double‐blind, placebo‐controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism , 2003, Movement disorders : official journal of the Movement Disorder Society.
[55] Donald A Robin,et al. Perceptions of effort during handgrip and tongue elevation in Parkinson's disease. , 2005, Parkinsonism & related disorders.
[56] A. Lawrence,et al. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease , 2005, Neurology.
[57] F. Micheli,et al. Quantitative study of salivary secretion in Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.
[58] A. Storch,et al. Increased periodontal pathology in Parkinson's disease , 2006, Journal of Neurology.
[59] G. Kenangil,et al. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline , 2007, Clinical Neurology and Neurosurgery.
[60] J. Trojanowski,et al. Nosology of Parkinson’s Disease: Looking for the Way Out of a Quackmire , 2005, Neuron.
[61] O. Rascol,et al. A study of salivary secretion in Parkinson's disease. , 1999, Clinical neuropharmacology.
[62] O. Doğu,et al. Ultrasound-guided versus ‘blind’ intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson’s disease , 2004, Clinical Neurology and Neurosurgery.
[63] S. Gilbert,et al. The effects of the combination of chlorhexidine/thymol- and fluoride-containing varnishes on the severity of root caries lesions in frail institutionalised elderly people. , 2004, Journal of dentistry.
[64] M. Youdim,et al. Regulation of protein kinase C by the anti‐Parkinson drug, MAO‐B inhibitor, rasagiline and its derivatives, in vivo , 2004, Journal of neurochemistry.
[65] Anthony H V Schapira,et al. Treatment options in the modern management of Parkinson disease. , 2007, Archives of neurology.
[66] D. Goldstein,et al. Neurocirculatory Abnormalities in Parkinson Disease With Orthostatic Hypotension: Independence From Levodopa Treatment , 2005, Hypertension.
[67] D. Goff,et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardi , 2007, Journal of the American Dental Association.
[68] R. Daroff,et al. Ophthalmologic features of Parkinson’s disease , 2004, Neurology.
[69] J. Jankovic. Parkinson’s disease: clinical features and diagnosis , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.
[70] M. Hoehn,et al. Parkinsonism , 1998, Neurology.
[71] Jack J. Chen,et al. Clinical Pharmacology of Rasagiline: A Novel, Second‐Generation Propargylamine for the Treatment of Parkinson Disease , 2005, Journal of clinical pharmacology.
[72] N. Newman,et al. Ophthalmologic features of Parkinson’s disease , 2004, Neurology.
[73] J. Atkins,et al. Laryngeal Findings in Advanced Parkinson's Disease , 2004, The Annals of otology, rhinology, and laryngology.
[74] H. McDade,et al. Repeated tongue and hand strength measurements in normal adults and individuals with Parkinson's disease. , 2005, The International journal of orofacial myology : official publication of the International Association of Orofacial Myology.
[75] Albert Hofman,et al. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. , 2005, Archives of neurology.
[76] Giovanna Pari,et al. Approach to diagnosis of Parkinson disease. , 2006, Canadian family physician Medecin de famille canadien.
[77] A. Friedman,et al. Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin. , 2001, Parkinsonism & related disorders.
[78] M. Panisset,et al. Salivary production in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.
[79] E. Wolters,et al. Management of non-motor symptoms in advanced Parkinson disease , 2008, Journal of the Neurological Sciences.
[80] E. D. Barnhart. Physicians Desk Reference , 1990 .
[81] I. Aydogdu,et al. Electrophysiological evaluation of pharyngeal phase of swallowing in patients with Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.
[82] J. Siegfried,et al. Changes in taste under L-DOPA therapy , 2004, Zeitschrift für Neurologie.
[83] D. Aarsland,et al. The psychosocial burden on spouses of the elderly with stroke, dementia and Parkinson's disease , 2002, International journal of geriatric psychiatry.
[84] B. R. Rothwell. Dental management of the medically compromised patient , 1987 .
[85] W. Poewe,et al. When a Parkinson’s disease patient starts to hallucinate , 2008, Practical Neurology.
[86] T. Clifford,et al. The dental awareness and needs of a Parkinson's disease population. , 1995, Gerodontology.
[87] V. Haroutunian,et al. The neuropathological basis for depression in Parkinson's disease. , 2009, Parkinsonism & related disorders.
[88] A. Lees,et al. Botulinum toxin A as treatment for drooling saliva in PD. , 2000, Neurology.
[89] Regina Katzenschlager,et al. Olfaction and Parkinson's syndromes: its role in differential diagnosis , 2004, Current opinion in neurology.
[90] M. Mori,et al. Oral Health Conditions in Patients with Parkinson’s Disease , 2004, Journal of epidemiology.
[91] A. Verma. Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease , 2008 .
[92] B. Seltzer,et al. Clinical and neuropsychological correlates of impaired awareness of deficits in Alzheimer disease and Parkinson disease: a comparative study. , 2001, Neuropsychiatry, neuropsychology, and behavioral neurology.
[93] N. Hockstein,et al. Sialorrhea: a management challenge. , 2004, American family physician.